O
ANAB icon

OrbiMed’s AnaptysBio ANAB Stock Holding History

OrbiMed’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-180,442
Closed -$2.66M – 150
2020
Q3 		$2.66M Sell
180,442
-195,358
-52% -$3.52M 0.03% 135
2020
Q2 		$8.39M Hold
375,800
– – 0.12% 106
2020
Q1 		$5.31M Hold
375,800
– – 0.09% 104
2019
Q4 		$6.11M Buy
+375,800
New +$8.89M 0.09% 98

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

OrbiMed's ANAB Position: Q4 2020 in Review

OrbiMed sold out of AnaptysBio (ANAB) in Q4 2020, closing a stake of 180,442 shares — an estimated $2.66M sold.

OrbiMed first reported a position in ANAB in Q4 2019 and held it in 4 quarters. The position peaked at $8.39M in Q2 2020. 136 funds tracked by Wall St. Rank hold ANAB as of Q4 2020.

  • OrbiMed reported no remaining AnaptysBio position as of Q4 2020 after selling out during the quarter.
  • OrbiMed sold 180,442 AnaptysBio shares in Q4 2020, an estimated $2.66M.
  • OrbiMed first reported a position in AnaptysBio in Q4 2019 and held it in 4 quarters.
  • OrbiMed's AnaptysBio position peaked at $8.39M in Q2 2020.
  • 136 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2020.

Based on OrbiMed's 13F filing for Q4 2020, filed 16 Feb 2021.